Skip to content

Clinical trial of the efficacy and safety of oral deferoxamine tablets in slowing the progression of myopia in children

Clinical trial of the efficacy and safety of oral deferoxamine tablets in slowing the progression of myopia in children

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074402
Enrollment
Unknown
Registered
2023-08-06
Start date
2023-08-03
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myopia

Interventions

control group:Wearing regular frames
experimental group:oral desipramine tablets with wearing regular frames

Sponsors

General Hospital of the Central Theater Command of People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 15 Years

Inclusion criteria

Inclusion criteria: 1.8-12 years old, gender is not limited; 2. Ciliary anesthesia computerized optometry SER between -1.00D and -5.00D in both eyes, astigmatism not more than 1.50D , BCVA = 4.9;

Exclusion criteria

Exclusion criteria: 1. Combined with other ocular diseases, such as various inflammatory diseases such as uveitis, glaucoma, cataract, fundus disease, ocular tumors, and any ocular pathology that affects visual function; 2. clinically abnormal slit-lamp findings; fundus findings = grade 2; dominant strabismus; abnormal intraocular pressure (intraocular pressure 21mmHg or difference in intraocular pressure between both eyes >5mmHg); and history of intraocular surgery; 3. Have participated or are currently participating in any myopia control clinical research trial within three months; 4. Previously used or currently using rigid corneal contact lenses (including care products), multifocal contact lenses, progressive multifocal lenses, and other specially designed myopia control lenses, feeder lenses, and low-concentration atropine-based drugs; 5. Patients with sucrose intolerance, fructose intolerance, glucose-galactose malabsorption syndrome or sucrase/isomaltase deficiency; Patients with immunocompromised status due to systemic diseases (e.g. diabetes mellitus, Down's syndrome, rheumatoid arthritis, psychiatric patients, etc.)

Design outcomes

Primary

MeasureTime frame
axial length;

Secondary

MeasureTime frame
spherical equivalent refractive ;corneal curvature;anterior chamber depth ;

Countries

China

Contacts

Public ContactChang Feng

General Hospital of the Central Theater Command of People's Liberation Army of China

wuhanmaple@126.com+86 130 9888 3737

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026